Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure.
作者信息
Cho Wonkyung J, Harden Destiny, Moreno Daiana, Dinulos James E, Hanna Paul E, Wang Qiyu, Kim Arthur Y, Sise Meghan E
机构信息
Massachusetts Eye and Ear Infirmary, Boston, MA, USA.
Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA, USA.
出版信息
Nephrol Dial Transplant. 2023 Jul 31;38(8):1912-1914. doi: 10.1093/ndt/gfad058.
Abstract
摘要
相似文献
1
Oral antiviral therapies for COVID-19 in patients with advanced chronic kidney disease or kidney failure.晚期慢性肾脏病或肾衰竭患者的 COVID-19 口服抗病毒疗法。
Nephrol Dial Transplant. 2023 Jul 31;38(8):1912-1914. doi: 10.1093/ndt/gfad058.
2
Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.新型冠状病毒病 2019 患者肾功能降低或丧失的治疗选择。
Adv Chronic Kidney Dis. 2020 Sep;27(5):434-441. doi: 10.1053/j.ackd.2020.09.001. Epub 2020 Sep 17.
3
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.直接作用抗病毒药物成功治疗终末期肾病患者和肾移植受者的丙型肝炎
Exp Clin Transplant. 2019 Feb;17(1):52-58. doi: 10.6002/ect.2018.0095.
4
Antiviral pills could change pandemic's course.抗病毒药丸可能会改变疫情的走向。
Science. 2021 Nov 12;374(6569):799-800. doi: 10.1126/science.acx9605. Epub 2021 Nov 11.
5
Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease.直接作用抗病毒药物治疗慢性肾脏病轻度至中度患者丙型肝炎病毒的疗效和安全性。
Nefrologia (Engl Ed). 2020 Jan-Feb;40(1):46-52. doi: 10.1016/j.nefro.2019.03.013. Epub 2019 Jun 19.
6
Treatment of COVID-19 in high-risk outpatients.高危门诊患者的新冠病毒病治疗
Med Lett Drugs Ther. 2022 Feb 7;64(1643):e1.
7
A National Strategy for COVID-19 Medical Countermeasures: Vaccines and Therapeutics.《COVID-19医疗应对国家战略：疫苗与治疗方法》
JAMA. 2022 Jan 18;327(3):215-216. doi: 10.1001/jama.2021.24165.
8
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.社论：非住院患者 SARS-CoV-2 感染的口服抗病毒药物治疗现状。
Med Sci Monit. 2022 Jan 1;28:e935952. doi: 10.12659/MSM.935952.
9
Real-world experience with mild-moderate COVID-19 therapies in kidney transplant patients: How to treat patients with chronic kidney disease from now on?肾移植患者中轻度至中度COVID-19治疗的真实世界经验：从现在起如何治疗慢性肾病患者？
Nefrologia (Engl Ed). 2024 May-Jun;44(3):433-435. doi: 10.1016/j.nefroe.2024.06.003. Epub 2024 Jun 25.
10
Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.进一步分析表明，对于新冠病毒病，奈玛特韦/利托那韦比莫努匹韦疗效更佳。
J Med Virol. 2024 Feb;96(2):e29464. doi: 10.1002/jmv.29464.
引用本文的文献
1
The Effect of Nirmatrelvir-Ritonavir on Short- and Long-term Adverse Outcomes From COVID-19 Among Patients With Kidney Disease: A Propensity Score-Matched Study.奈玛特韦-利托那韦对肾病患者新冠病毒病短期和长期不良结局的影响：一项倾向评分匹配研究
Open Forum Infect Dis. 2024 Dec 31;12(1):ofae756. doi: 10.1093/ofid/ofae756. eCollection 2025 Jan.
2
Management of Kidney Transplant Outpatients With COVID-19: A Single Center Experience.COVID-19 肾移植门诊患者的管理：单中心经验。
Transpl Int. 2024 Sep 26;37:12920. doi: 10.3389/ti.2024.12920. eCollection 2024.
3
Comparison of safety and efficacy between Nirmatrelvir-ritonavir and molnupiravir in the treatment of COVID-19 infection in patients with advanced kidney disease: a retrospective observational study.奈玛特韦-利托那韦与莫努匹拉韦治疗晚期肾病患者新冠病毒感染的安全性和疗效比较：一项回顾性观察研究
EClinicalMedicine. 2024 May 3;72:102620. doi: 10.1016/j.eclinm.2024.102620. eCollection 2024 Jun.
4
Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19.莫努匹韦和奈玛特韦-利托那韦对新冠病毒感染的慢性肾脏病患者的疗效
Kidney Int Rep. 2024 Feb 9;9(5):1244-1253. doi: 10.1016/j.ekir.2024.02.009. eCollection 2024 May.
本文引用的文献
1
COVID drug drives viral mutations - and now some want to halt its use.新冠药物促使病毒突变——现在一些人希望停止使用它。
Nature. 2023 Feb;614(7948):399. doi: 10.1038/d41586-023-00347-z.
2
Early Experience with Modified Dose Nirmatrelvir/Ritonavir in Dialysis Patients with Coronavirus Disease 2019.COVID-19 透析患者中使用奈玛特韦/利托那韦改剂量后的早期经验。
Clin J Am Soc Nephrol. 2023 Apr 1;18(4):485-490. doi: 10.2215/CJN.0000000000000107. Epub 2023 Mar 1.
3
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.口服尼马曲韦/利托那韦（一种治疗 COVID-19 的蛋白酶抑制剂）在肾功能损害患者中的药代动力学。
Clin Pharmacol Ther. 2022 Oct;112(4):892-900. doi: 10.1002/cpt.2688. Epub 2022 Jul 5.
4
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19.奈玛特韦片/利托那韦片组合包装口服药用于伴有进展为重症高风险因素的 COVID-19 门诊患者。
N Engl J Med. 2022 Apr 14;386(15):1397-1408. doi: 10.1056/NEJMoa2118542. Epub 2022 Feb 16.
5
The Impact of Vaccination on Incidence and Outcomes of SARS-CoV-2 Infection in Patients with Kidney Failure in Scotland.接种疫苗对苏格兰肾衰竭患者 SARS-CoV-2 感染发生率和结局的影响。
J Am Soc Nephrol. 2022 Apr;33(4):677-686. doi: 10.1681/ASN.2022010046. Epub 2022 Feb 2.
6
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.奥密克戎变异株对抗体介导的中和作用具有高度抗性：对控制 COVID-19 大流行的影响。
Cell. 2022 Feb 3;185(3):447-456.e11. doi: 10.1016/j.cell.2021.12.032. Epub 2021 Dec 24.
7
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.莫努匹韦片用于非住院 COVID-19 患者的口服治疗。
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
8
New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.新型基于肌酐和胱抑素 C 的估算肾小球滤过率方程，无需考虑种族因素。
N Engl J Med. 2021 Nov 4;385(19):1737-1749. doi: 10.1056/NEJMoa2102953. Epub 2021 Sep 23.
9
Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD.慢性肾脏病患者对SARS-CoV-2疫苗接种的早期免疫反应综述
Kidney Int Rep. 2021 Sep;6(9):2292-2304. doi: 10.1016/j.ekir.2021.06.027. Epub 2021 Jul 6.
10
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States.美国重症监护病房中患有基础肾脏疾病的 COVID-19 患者的特征和结局。
Am J Kidney Dis. 2021 Feb;77(2):190-203.e1. doi: 10.1053/j.ajkd.2020.09.003. Epub 2020 Sep 19.
Zotero 插件